Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

The present invention provides methods of producing, purifying and expanding mDA progenitor cells.

Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

Disclosed is a method for producing kidney organoids including steps of: (1) differentiating stem cells into metanephric mesenchyme cells; (2) forming metanephric mesenchyme cell aggregates by culturing the metanephric mesenchyme cells; and (3) differentiating the metanephric mesenchyme cell aggregates into kidney organoids.

A population of brain pericyte-like cells, wherein the cells express pericyte markers but do not express ACTA2 and wherein the cells are generated from hPSCs, is disclosed herein.

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.

Disclosed herein are compositions and methods of enhancing stem cell differentiation into beta cells with use of one or more epigenetic modification compounds. The present disclosure also relates to compositions and methods of sorting and enriching the differentiated beta cells. The present disclosure also relates to compositions and methods of irradiating cell population for reducing proliferation.

The present invention chiefly aims to provide a new differentiation inducing agent (peptide) that can solve the previous problems in inducing differentiation of pluripotent stem cells such as ES/iPS cells into somatic cells (e.g., cardiomyocytes).

The present invention can include, for example, a synthetic peptide having, in the molecular structure thereof, an amino acid sequence represented by the following (SEQ ID NO: 1), or an amino acid sequence formed by substitution, deletion and/or addition of one or several amino acid residues in the amino acid sequence. It can also include, for example, a composition for inducing differentiation of pluripotent stem cells into somatic cells, comprising said synthetic peptide.

TABLE-US-00001 (SEQ ID No. 1) C A X X L X X L X X X L X X L X G X X X X X X X X X X X X X X L X X X L X X L X X A C                                                                  • • • 

This disclosure relates to method of differentiating stem cells to specific cardiac-like cells. In certain embodiments, the disclosure contemplates methods of generating left ventricular-like cells and the atrial-like cells by timing the exposure of dividing stem cells to retinoic acid (RA) or retinoic acid receptor inhibitors.

Methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro are provided. Compositions and systems of cell populations of TEP cells as well as cells formed during different stages of differentiation of PS cells into TEP cells are also disclosed. The methods, isolated in vitro cell populations, compositions, and systems disclosed provide functional TEP cells that mature into thymic epithelial cells in vivo.